Navigation Links
Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
Date:7/14/2009

LAGUNA NIGUEL, Calif., July 14 /PRNewswire/ -- Inspiration Biopharmaceuticals today announced the presentation of positive preclinical safety, toxicology and preliminary pharmacokinetic data on its lead product, IB1001, a novel recombinant Factor IX product to treat patients with hemophilia B. The data were highlighted in an oral presentation yesterday at the XXII Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Boston, Mass. IB1001 has completed preclinical testing and is currently being evaluated in a Phase 1/2-3 clinical study.

In the study, the safety, toxicology and pharmacokinetics of IB1001 were evaluated in animal models and compared to commercially available Factor IX products. Results showed that IB1001 has an excellent safety profile in animal models and a similar pharmacokinetic profile when compared to currently available Factor IX products.

"These results and the progress that we have made in advancing our protein manufacturing technology have facilitated the advancement of IB1001 into a Phase 1/2-3 clinical program," said Michael Griffith, Ph.D., President and CEO, Inspiration Biopharmaceuticals. "Our ultimate goal is to increase accessibility to prophylactic treatment and improve the quality of life for people suffering from hemophilia around the world. We expect to move IB1001 into a pivotal trial and look forward to updating you on all developments related to this program."

About IB1001

IB1001 is an intravenous recombinant Factor IX product for the acute and preventative treatment of the bleeding disorder associated with hemophilia B. IB1001 is produced with Inspiration's proprietary recombinant protein manufacturing technology, which significantly increases cell-line productivity.

About Hemophilia

Hemophilia is a lifelong, inherited bleeding disorder cause
'/>"/>

SOURCE Inspiration Biopharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
2. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
3. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
4. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
6. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
7. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
8. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
9. The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... (PRWEB) September 19, 2014 Barnhardt ... Product Label for its Organic Cotton . The ... amount of renewable biobased ingredients meets or exceeds levels ... materials composed in whole or in significant part of ... will allow our Organic cotton to be immediately identified ...
(Date:9/18/2014)... September 18, 2014 Bipartisan passage this ... bill designed to stimulate development and commercialization of new ... praised by leaders of SPIE, the international society ... American Manufacturing and Innovation (RAMI) Act, now moves to ... have said they are optimistic that it will win ...
(Date:9/18/2014)... -- Health Enhancement Products, Inc. (OTCQB: HEPI), a Michigan ... metabolic processes, is pleased to announce the addition of a ... Nola E. Masterson , a California -based ... 17, 2014. "We,re very pleased and honored ... Andrew Dahl , President and CEO. "She joins us ...
(Date:9/18/2014)... 2014 Research and Markets ... N-acetylcysteine Industry Report 2014" report to their ... Report 2014 is a professional and in-depth study ... industry. The report provides a basic ... and industry chain structure. The N-acetylcysteine market analysis ...
Breaking Biology Technology:Barnhardt Manufacturing Company Earns USDA Certified Biobased Product Certification and Label for Organic Cotton 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 3Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Global N-acetylcysteine Industry Report 2014 2
... 10, 2009, NeoStem, Inc. (NYSE Alternext US: NBS) (the ... "Alternext") indicating that the Company is not in compliance ... "Guide"), which requires a listed company to hold meetings ... Company had announced that it planned to hold a ...
... ITMN ) today announced the pricing of an underwritten ... The last reported sale price of InterMune,s common stock on ... $17.96. The offering is expected to close on or ... All of the shares are being sold by the company.UBS ...
... Pharmacyclics, Inc.,(Nasdaq: PCYC ) today reported financial ... net loss for the second quarter of fiscal 2009,was $4.8 ... of $5.9 million,or $0.23 per share, in the second quarter ... expenses were $4.9 million in the second quarter of fiscal,2009, ...
Cached Biology Technology:NeoStem Receives Notice of Noncompliance from NYSE Alternext US 2InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock 2Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 2Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 3Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 4Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 5Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 6Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 7
(Date:9/21/2014)... warming, are set to rise again in 2014 - reaching ... per cent projected rise in burning fossil fuels is revealed ... UK by researchers at the Tyndall Centre for Climate Change ... of Engineering, Mathematics and Physical Sciences at the University of ... Summit, where world leaders will seek to catalyse action on ...
(Date:9/21/2014)... California, San Diego, have developed a program that predicts ... of genes based on sequences of DNA. They describe ... human embryonic cells in a paper published in ... our cells have the same blueprint, the same DNA, ... author of the report. "Skin cells protect, nerve cells ...
(Date:9/21/2014)... strains of bacteria have emerged that resist even the ... forms of tuberculosis and staphylococcus, infect more than 2 ... the urgent need for new treatments, scientists have discovered ... decade. , MIT engineers have now turned a powerful ... that can disable any target gene, they have shown ...
Breaking Biology News(10 mins):CO2 emissions set to reach new 40 billion ton record high in 2014 2CO2 emissions set to reach new 40 billion ton record high in 2014 3Program predicts placement of chemical tags that control gene activity 2Battling superbugs 2Battling superbugs 3Battling superbugs 4
... from ESA,s Envisat satellite radar are being used to ... Globe solo round-the-world yacht race. CLS, a subsidiary ... new radar applications division (formerly the BOOST Technologies Company), ... Envisat radar imagery to operationally observe oceans at high ...
... seascape that cleaves earlier each springthey may find relief in ... changes in the timing of sea-ice breakup and of snow ... least some polar bears with an alternative source of food. ... "Over 40 years, six subadult male bears were seen among ...
... battle against invading bacteria reaches its peak activity at ... Experiments with the laboratory model organism, Drosophila melanogaster, reveal ... with the body,s circadian rhythm, according to Stanford researchers ... Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 ...
Cached Biology News:Vendee Globe route seen from above 2Goose eggs may help polar bears weather climate change 2Immunity stronger at night than during day 2